• UNIT
    Box
  • Formula

    Mebendazole..........................................................500 mg
    Excipients q.s............................................................ 1 tablet

  • Dosage forms

    Chewable tablets.

  • Packing specification

    Box of 1 blister x 1 chewable tablet.

  • Driving and operating machinery

    The drug can cause dizziness; use with caution in drivers and machinery users.

  • CAREFUL

    Mebendazole should be used with caution in children aged < 2 years. Some reports e.g., neutrophilopenia and impaired hepatic function, including hepatitis have been recorded in patients treated at dosage substantially higher than recommended or for prolonged periods of time.

  • PREGNANT AND LACTATING WOMEN

    The safety of mebendazole has not been determined in pregnant women. Therefore, do not administer to pregnant women, particularly in the first trimester. Whether the drug is secreted into breast milk or not, the drug is used with caution during the nursing period.

  • DRUG INTERACTIONS

    Concurrent treatment with cimetidine may inhibit the metabolism of mebendazole in the liver, resulting in increased plasma concentrations of mebendazole. Concomitant use of mebendazole and phenytoin or carbamazepine reduces the plasma mebendazole concentration.

  • UNWANTED EFFECTS

    Infrequently: dizziness, abdominal pain, diarrhea, cases of worms crawling out of the mouth and nose.
    Rarely: rash, urticaria, angioedema, convulsion.
    Inform your physician about any adverse effects occur during the treatment.

  • OVERDOSE AND TREATMENT

    In the event of accidental overdosage, gastrointestinal complaints last up to a few hours may occur. Induced emesis and cathartic, including activated charcoal may be given.

  • STORAGE CONDITIONS

    Store in dry places, not exceeding 30°C, protect from light.

  • Materiality

    Fubenzon contains the active ingredient - mebendazole, which is a benzimidazole broad-spectrum anthelmintic derivative. Mebendazole produces the high effect in the adult and larval stages of roundworms (Ascaris lumbricoides), threadworm (Enterobius vermicularis), whipworms (Tricuris trichiura), hookworms (Ancylostoma duodenale) and Necator americanus, and Capillaria philippinensis. The drug also destroys the ova of roundworms and whipworms. The drug has been tried in high doses in the treatment of hydatid disease.
    The drug interferes with the synthesis of tubular micro-structure, so it inhibits the generation of the helminths. In addition, mebendazole irreversibly blocks the uptake of glucose by the helminths.
    Oral bioavailability of the drug is < 20%. However, dosing with a high-fat meal leads to a significant increase in the absorption of mebendazole. The drug is about 95% bound to plasma proteins. The drug is mainly metabolised in the liver and is eliminated by the bile and the faeces.

  • Expiry
    36 months from the manufacturing date.
  • Indication

    For the treatment of common roundworm, hookworm, whipworm, pinworm, eelworm in single or mixed infections.

  • Contraindicated

    Hypersensitivity to any components of the drug. Pregnant women. Severe hepatic disease.

  • DOSAGE AND HOW TO USE

    Chew the tablet before swallowing with a little water.
    Adults and children aged > 2 years: one tablet (500 mg) as a single dose.
    The same dosage should be periodically administered every 4 to 6 months.
    Or as directed by the physician.
    Read the directions carefully before use.
    Consult the physician for more information.